Table V.
Pathological stage and Gleason score according to postoperative PSADT in 51 patients with PSA recurrence.
| Pathological stage, n (%) | Specimen Gleason score, n (%) | |||||||
|---|---|---|---|---|---|---|---|---|
| Post-PSADT (months) | No. of patients | pT2 | pT3a (EPE+) | pT3b (SV+) | pN+ (LV+) | 2–6 | 7 | 8–10 |
| <6 | 23 | 2 (8.7) | 11 (47.8) | 8 (34.8) | 2 (8.7) | 0 (0) | 11 (47.8) | 12 (52.2) |
| 6.0–11.9 | 13 | 8 (61.5) | 5 (38.5) | − | – | 3 (23.2) | 5 (38.4) | 5 (38.4) |
| 12.0–17.9 | 6 | 4 (66.7) | 2 (33.3) | − | – | 2 (33.3) | 2 (33.3) | 2 (33.3) |
| 18.0–23.9 | 1 | – | 1 (100) | − | – | – | – | 1 (100) |
| ≥24.0 | 8 | 7 (87.5)a | 1 (12.5) | 0 | 0 | 2 (25) | 4 (50) | 2 (25) |
a
P=0.004. Post-PSADT, postoperative prostate specific antigen doubling time; n, number of patients; pT2, confined prostate cancer; EPE+, extra prostatic extension positive; SV+, seminal vesicle invasion positive; LV+, lymph node metastasis positive.